Today: 8 February 2026
Subscribe
Browse Category

NASDAQ:ARQT News 30 December 2025 - 12 January 2026

Arcutis Biotherapeutics stock slides after 2026 ZORYVE sales outlook; June FDA deadline in focus

Arcutis Biotherapeutics stock slides after 2026 ZORYVE sales outlook; June FDA deadline in focus

Arcutis Biotherapeutics shares fell 8.7% to $25.76 Monday after the company set a 2026 net product sales target of $455–$470 million for its ZORYVE franchise. The company reported $99.2 million in net product revenue last quarter and ended September with $191.4 million in cash. Arcutis plans to expand its sales team by 20% and expects key clinical trial data in early 2026. The stock hit a session low of $25.51.
12 January 2026
··
Arcutis stock sinks 5% after wild swing as traders eye Fed, FDA clock and earnings

Arcutis stock sinks 5% after wild swing as traders eye Fed, FDA clock and earnings

Arcutis Biotherapeutics shares fell 5.3% to $28.29 Friday after an early surge, tracking a shift in rate expectations following a soft U.S. jobs report. Broader biotech indexes rose. Investors are watching for Arcutis’ next earnings on Feb. 24 and an FDA decision on ZORYVE for children by June 29. The Fed’s late-January meeting remains a key focus for traders.
9 January 2026
···
Arcutis stock (ARQT) in focus after insider sale notice as U.S. markets shut for New Year’s Day

Arcutis stock (ARQT) in focus after insider sale notice as U.S. markets shut for New Year’s Day

Arcutis Biotherapeutics shares closed up 3.4% at $29.04 in the final trading session of the year. A Form 144 filing showed Chief Medical Officer Patrick Burnett plans to sell 1,697 shares after acquiring them through restricted stock vesting. U.S. stock markets are closed Thursday for New Year’s Day and reopen Friday. The stock’s move contrasted with a broader market pullback.
1 January 2026
·
Arcutis Biotherapeutics stock pops today as ARQT bucks biotech dip into year-end trade

Arcutis Biotherapeutics stock pops today as ARQT bucks biotech dip into year-end trade

NEW YORK, December 31, 2025, 10:33 ET — Regular session Shares of Arcutis Biotherapeutics Inc rose 3.8% to $29.16 by 10:33 a.m. ET on Wednesday, extending gains in the final U.S. trading session of 2025. The Nasdaq-listed dermatology drugmaker traded between $28.08 and $29.19, with about 181,000 shares changing hands. The move puts ARQT within striking distance of $30 and about 8% below its 52-week high of $31.75, a level closely watched by momentum investors. The stock’s 52-week low stands at $11.14, according to market data. markets.businessinsider.com That relative strength mattered on a down day for risk assets. The biotech
31 December 2025
··
Arcutis Biotherapeutics stock slides today as biotech pulls back, ARQT down nearly 3%

Arcutis Biotherapeutics stock slides today as biotech pulls back, ARQT down nearly 3%

NEW YORK, December 30, 2025, 14:45 ET — Regular session Arcutis Biotherapeutics shares fell 2.9% to $27.74 in afternoon trading on Tuesday, after moving between $27.72 and $28.65. Volume was about 0.6 million shares. The drop outpaced broader biotech gauges, with the SPDR S&P Biotech ETF down about 1.5% and the iShares Nasdaq Biotechnology ETF off about 1.1%. That matters for Arcutis because it trades as a growth story tied to one product franchise, leaving the stock prone to outsized moves when sentiment sours across biotech and high-multiple names. Arcutis is a commercial-stage medical dermatology company whose main product, Zoryve
30 December 2025
·

Stock Market Today

Keppel stock price in focus as broker lifts target and dividend clock ticks

Keppel stock price in focus as broker lifts target and dividend clock ticks

8 February 2026
Keppel shares closed at S$11.64 on Friday, up 0.17%, outperforming the Straits Times Index. UOB Kay Hian raised its target price to S$13.23 after Keppel announced a 38% higher FY2025 dividend, with key dates set for April. The M1 sale remains delayed pending regulatory approval. Investors await updates on asset sales and dividend plans when trading resumes Monday.
DBS share price: DBS Group Holdings stock in focus before Feb 9 earnings

DBS share price: DBS Group Holdings stock in focus before Feb 9 earnings

8 February 2026
DBS closed at S$59.30 on Friday, down 0.6%, ahead of its full-year results due before market open on Feb. 9. Singapore shares fell 0.8% the same day as regional markets slid. Investors await updates on DBS’s margins and capital return plan. Singapore’s Budget 2026 is set for Feb. 12, with UOB and OCBC results later this month.
Go toTop